1 Steinberg D. Atherogenesis in perspective:hypercholsterolemia and inflammation as partners in crime[J].Nat Med, 2002, 8:1211-1217.2 Maiolino G, Rossitto G, Caielli P, et al. The role ofoxidized low-density lipoproteins in atherosclerosis:The myths and the facts[J]. Mediators of Inflam, 2013,2013:714653.3 Itabe H. Oxidized low-density lipoprotein asa biomarker of in vivo oxidative st ress:f romatherosclerosis to periodontitis[J]. J Clin BiochemNutr, 2012, 51:1-8.4 Fang R, Zhang N, Wang C, et al. Relations betweenplasma ox-LDL and carotidplaque among ChineseHan ethnic group[J]. Neurol Res, 2011, 33:460-466.5 汪颖, 杜丽娜, 金义光. 抗氧化剂的临床应用及其研究进展[J]. 国际药学研究杂志, 2009, 36:465-466.6 廖序东, 蔡丽娥. 普罗布考对急性冠脉综合征患者抗氧化作用的影响[J]. 中国城乡企业卫生, 2015, 1:5-7.7 孟晓萍, 王素香, 张基昌, 等. 普罗布考联合降脂药物对动脉粥样硬化病人的干预治疗[J]. 中华医学杂志,2009, 89:1986-1988.8 李强, 凌芳, 聂德云, 等. PAS三联疗法对急性脑梗死患者血清相关蛋白及颈动脉易损斑块的影响[J]. 中华神经医学杂志, 2013, 12:44-49.9 马璟曦, 蔡敏. 普罗布考联合阿托伐他汀对急性脑梗死患者颈动脉粥样硬化斑块的影响[J]. 重庆医学,2013, 42:1835-1840.10 邹春颖, 于凤伟, 高凤荣. PAS方案治疗动脉粥样硬化血栓形成型脑梗死的疗效[J]. 中国老年学杂志, 2011,31:2205-2206.11 陈晓, 杨敏, 付睿, 等. 瑞舒伐他汀联合普罗布考治疗颈动脉易损粥样硬化斑块的疗效临床随机对照研究[J]. 中国全科医学, 2013, 16:2799-2802.12 Liu J, Li M, Lu H, et al. Effects of probucol onrestenosis after percutaneous coronary intervention:asystematic review and meta-analysis[J]. PLoS One,2015, 10:e0124021. |